Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2

7 Oct 2024

Abstract excerpt

SARS-CoV-2 Omicron sublineages escape most preclinical/clinical neutralizing antibodies in development, suggesting that previously employed antibody screening strategies are not well suited to counteract the rapid mutation of SARS-CoV-2. Therefore, there is an urgent need to screen better broad-spectrum neutralizing antibody. In this study, a comprehensive approach to design broad-spectrum inhibitors against both...

Topics

Join the communities discussing this publication.

Monoclonal and Polyclonal Antibodies Research
SARS-CoV-2 and COVID-19 Research
vaccines and immunoinformatics approaches

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39373693
DOI: 10.1002/advs.202402975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2PMID 39373693Read ↗

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2Semantic proximity Read ↗

Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster modelsSemantic proximity Read ↗

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralizationSemantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variantsSemantic proximity Read ↗

Engineered Multivalent Nanobodies Potently and Broadly Neutralize SARS‐CoV‐2 VariantsSemantic proximity Read ↗

Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2Semantic proximity Read ↗

Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Semantic proximity Read ↗

A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variantsSemantic proximity Read ↗

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administrationSemantic proximity Read ↗

Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations.Semantic proximity Read ↗

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escapeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.